Navigation Links
Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting
Date:2/13/2008

Investigators to Report use of the Cancion(R) System in Patients

Hospitalized with Heart Failure

LAKE FOREST, Calif., Feb. 13 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to treat heart failure, announced today that the company's MOMENTUM Trial Abstract was accepted for Late Breaking Clinical Trial presentation at the upcoming annual American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial evaluated the percutaneous Cancion System in patients with acute decompensated heart failure.

Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and National Principal Investigator for the MOMENTUM Trial, will present, "Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results of the MOMENTUM Trial," Tuesday, April 1, 2008, from 1:45 pm to 2:00 pm, at the McCormick Place convention center, North Hall B1.

"MOMENTUM is a landmark study examining the hemodynamic and clinical effects of the Cancion System in managing patients hospitalized with heart failure inadequately responsive to medical therapy," stated Dr. Barry Greenberg. Mr. Ken Charhut, President and CEO added, "We are delighted that the MOMENTUM Trial Abstract has been accepted for presentation at the ACC conference and look forward to Dr Greenberg's presentation and dialogue."

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held, medical device company seeking to redefine heart failure therapy by developing products that prevent or reverse the underlying disease progression and provide new treatment options to the clinical community to improve patient outcomes and quality of life.

Orqis Medical develops innovative devices that utilize aortic flow augmentation to improve cardiac performance. The percutaneous Cancion System has secured the CE mark and is currently awaiting clearance in the U.S. for extracorporeal support. The implantable Exeleras(R) System is under development.

For more information on Orqis Medical, please visit http://www.orqis.com

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hooper Holmes Concludes Sale of Medicals Direct
2. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
3. Black AIDS Mobilization Gains Momentum with Congressional Black Caucus Call to Action
4. Eclipsys Announces Strong Market Momentum for Sunrise Pharmacy
5. World Cancer Campaign Builds Momentum Globally with International Initiative to Protect Children From Secondhand Smoke
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... 27, 2017 , ... GAFFEY Healthcare, a leading provider of ... to Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice ... executive officer (CEO). , Elrene has been with company since Oct 2014 and ...
(Date:7/27/2017)... Salt Lake City, Utah (PRWEB) , ... July 27, 2017 , ... Healthy eating isn’t ... of fruits and vegetables. At the same time, many Americans overeat refined grains and sugar. ... is that 36 percent of adults in the U.S. are obese. , As a culture, ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Freedom ... form startup companies around 117 breakthrough inventions from 55 institutions, including the National ... National Institute of Biomedical Imaging and Bioengineering), the United States Army, and more ...
(Date:7/27/2017)... GREENWOOD VILLAGE, CO (PRWEB) , ... July 27, 2017 , ... ... According to the National Funeral Directors Association, this trend is expected to continue with ... this trend, there is a growing demand for new innovations that enable families to ...
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., knows ... yet seen an effective and dignified way to keep leeches in place during therapy," ... , This invention provides an effective way to keep a leech in place on ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/28/2017)... FLINT, Mich. , July 28, 2017 EnvoyHealth, ... (CMT) to pilot a program for CleverCap LITE, a ... CMT strives to deliver innovative health technology solutions ... adherence. CleverCap LITE ... The compact, high-tech bottle cover: ...
(Date:7/27/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... 2017.  The Company reported second quarter net sales of ... year period, and an increase of 2.1% on a ... contribution from the LDR Holding Corporation acquisition, second quarter ... 2016, or 0.3% on a constant currency basis. ...
Breaking Medicine Technology: